Search PubMed⌕ Search

Biomedical subjects

H H Fernandez

Publications and source records attributed to H H Fernandez.

28 records · Page 2Linked to original sources
PubMed2000

Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. SAGE Study Group. Systematic Assessment and Geriatric drug use via Epidemiology.

OBJECTIVE: To determine gender differences in the prevalence, survival rates, and management of noncognitive behavioral problems of patients with Parkinson's disease (PD) in nursing homes (NH). METHODS: We performed an observational study on 24,402 residents with PD using the Systematic Assessment and Geriatric drug use via Epidemiology (SAGE) database collected from the Minimum Data Set on a cross-section of over 400,000 NH residents in five US states. Gender differences in behavior were used to predict differences in pharmacologic and nonpharmacologic therapies using logistic regression. Similar analyses were done to evaluate gender differences in 1-year survival rates among patients with PD with and without behavioral problems. RESULTS: 36% of men and 33% of women exhibited behavioral problems. Wandering, verbal and physical abusiveness, and inappropriate behavior tended to be more common in men, especially among PD residents with severe cognitive impairment. Hallucinations and delusions were equally prevalent between genders and depressive symptoms were more common in women. Regardless of behavioral manifestation, men were more likely to receive antipsychotic drugs, whereas women were more likely to receive antidepressants. This gender difference in treatment was also widest among the severely demented group. Although women lived longer, no difference in survival curves were noted between PD residents with and without behavioral problems. CONCLUSION: Gender appears to play an important role in determining the frequency and treatment of behavioral problems of NH residents with PD.

Activities of Daily Living↗
PubMed1999

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

Quetiapine is an atypical antipsychotic with clozapine-like pharmacology but without associated agranulocytosis. We report our complete experience with quetiapine for the treatment of drug-induced psychosis (DIP) in Parkinson's disease (PD). Thirty-five patients with PD and DIP aged 75 years (range, 58-89) with a mean PD duration of 8.4 years on an average of 427 mg levodopa per day received a mean dose of 40.6 mg quetiapine daily. Twenty of 24 neuroleptic-naive patients reported marked improvement of psychosis without a decline in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS-motor). Ten patients had a baseline and 4-week follow-up assessment using the Mini-Mental Status Examination (MMSE) and Brief Psychiatric Rating Scale (BPRS). The improvement in BPRS score (32.6 versus 22.8) was clinically and statistically significant (p = 0.024). Three of 24 were unable to tolerate quetiapine because of orthostatic hypotension, headache, nausea, and persistence of hallucinations. One patient died of an unrelated cause. We also tried to switch 11 psychiatrically stable patients on clozapine (eight) and olanzapine (three). Five patients made this transition without a loss of effect as measured on BPRS and MMSE. Six did not (five on clozapine, one on olanzapine) because of confusion, erratic behavior, and increased hallucinations. No crossover failure had worsened PD except for increased tremor in one. Quetiapine is useful and well-tolerated as a first drug to treat DIP in PD but must be used cautiously to replace other atypical antipsychotic drugs.

Aged↗
PubMed1999

Punding on L-dopa.

"Punding" is a stereotypical motor behavior in which there is an intense fascination with repetitive handling and examining of mechanical objects, such as picking at oneself or taking apart watches and radios or sorting and arranging of common objects, such as lining up pebbles, rocks, or other small objects. It is thought to be dopamine-related although only a single report of punding in a patient with Parkinson's disease (PD) resulting from L-dopa has been reported. We describe three additional cases. All were women aged 65-72 years with a PD duration between 10 and 20 years, on 500-1900 mg L-dopa per day. One spent hours in the market fascinated by cans. At home she endlessly examined and catalogued her jewelry. Another picked threads in rugs indoors and weeded her garden compulsively to the point of wetting herself rather than stopping. The third hoarded flashlights taking them apart and reassembling them. All improved with reduction of their anti-PD medications. We think punding is an uncommon but overlooked complication of dopaminergic drugs.

Aged↗
PubMed1999

Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities. SAGE Study Group.

Despite the high prevalence of Parkinson's disease (PD) in the elderly, little information is available regarding the epidemiology of the disease in residents in long-term care facilities. Using a population-based database with over 470,000 residents (1992-1996) of all Medicare- or Medicaid-certified nursing homes of five states, we identified 24,402 residents with a diagnosis of PD. We examined data collected with the federally mandated Minimum Data Set, and sociodemographic, clinical, and treatment information. The prevalence of PD in nursing homes was 5.2%, with peak age-specific prevalence between ages 75 and 84 years. Seventy percent of patients had moderate to severe cognitive impairment, and over 80% had moderate to severe functional disability. Less than 10% had verbal and physical signs of grief and anxiety, and 80% exhibited poor psychosocial well-being, yet only 15% were actively treated for depression. Only 44% received antiparkinsonian drugs. Female gender, black race, age, level of cognitive impairment, and level of physical functioning were inversely related to the likelihood of receiving one of these drugs. When antipsychotic drugs were administered (15%), only 1% were atypical agents. Although PD is a relatively common diagnosis among nursing home residents, pharmacologic management of these individuals appears to be less than optimal.

Aged↗
PubMedDate not supplied

Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?

BACKGROUND: Positron emission tomography (PET) cameras are expensive and scarce, and the tests are non-reimbursable. A less costly and more available test such as a single photon emission computed tomography (SPECT) may be helpful in the diagnosis of early or atypical Parkinson's disease (PD) if its sensitivity is comparable to a PET scan. Altropane is an iodinated form of the N-allyl analog of WIN 35,428 which acts as a dopamine transport inhibitor. When radiolabeled with the gamma emitting isotope [123I], altropane serves as a SPECT ligand with high affinity and selectivity for the dopamine transporter. It is a good marker for dopamine neurons and is useful in detecting PD. MATERIAL AND METHODS: We describe 2 patients with typical, early PD and their [123I]-altropane SPECT and [18F]-6-flouroDOPA PET scan results which were performed within a three-month interval. PET studies were performed using a PC-4096 scanner (Scanditronix AB, Sweden) with 15 axial slices and resolution of 6 mm FWHM. The SPECT acquisitions were performed on a MultiSPECT gamma camera (Siemens, Hoffman Estates, IL) equipped with fan-beam collimators with an intrinsic resolution of 4.6 FWHM (for Case 1) and a DSI Ceraspect camera with an annular crystal, with resolution of approximately 6.4 mm FWHM (for Case 2). RESULTS: Both patients, aged 54 and 38 years, had a one-year history of intermittent right hand tremor with right arm rigidity and hypokinesia and bradykinesia on fine finger movements. A significant and sustained improvement of their parkinsonian symptoms was noted using a dopamine agonist. SPECT and PET scans showed non-diagnostic fluoroDOPA PET scans with clear unilateral striatal reduction of tracer uptake contralateral to their parkinsonian side on altropane SPECT scans. CONCLUSIONS: Altropane SPECT may be an accessible and sensitive imaging modality for detecting early PD. Further and more controlled studies are needed to define its potential role in detecting presymptomatic, early and atypical PD cases.

Adult↗